LIBX-A402 is a selective, ATP-dependent inhibitor of ACSL4 (hACSL4, IC50=0.33 µM, Kd=3.3 µM) and an inhibitor of ferroptosis. LIBX-A402 targets the fatty acid-binding pocket of ACSL4 and prevents cells from undergoing ferroptosis. LIBX-A402 can be used in the research of cancer and Parkinsons disease[1].
Molecular Weight:
293.32
Purity:
98.71
Formula:
C18H15NO3
Target:
ACSL Family,Ferroptosis
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
